Capecitabine safety profile, innovative and generic adjuvant formulation of nonmetastatic colorectal cancer
Objective: To analyze adverse reactions in patients with nonmetastatic colorectal cancer due to treatment with either innovative or generic capecitabine and/or to the chemotherapeutic regimen employed, to the capecitabine alone, or in combination with oxaliplatin (XELOX).Method: Descriptive retros...
Збережено в:
| Опубліковано в:: | Farmacia Hospitalaria |
|---|---|
| Автори: | , , , |
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Sociedad Española de Farmacia Hospitalaria
2019
|
| Предмети: | |
| Онлайн доступ: | https://www.redalyc.org/articulo.oa?id=365961518001 https://www.redalyc.org/journal/3659/365961518001/ https://www.redalyc.org/journal/3659/365961518001/html/ https://www.redalyc.org/journal/3659/365961518001/365961518001.epub https://www.redalyc.org/journal/3659/365961518001/movil |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|